Comment on: Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: open label, randomized, controlled trial

Rheumatology (Oxford). 2019 May 1;58(5):925. doi: 10.1093/rheumatology/kez033.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived
  • Cyclophosphamide
  • Humans
  • Lung Diseases*
  • Rituximab
  • Scleroderma, Diffuse*

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
  • Cyclophosphamide